Retrospective Observational Study of Cotrimoxazole Dosing in Intensive Care Unit

Centre Hospitalier Universitaire de Saint Etienne

Status: Completed

Conditions: Acute Kidney Injury

Treatments: Other: Collect data of medical record

Study type: Observational

Funder types: Other

Identifiers

NCT05221216

IRBN1452021/CHUSTE

Details and patient eligibility

About

Trimethoprim/sulfamethoxazole (TMP/SMX, cotrimoxazole) is the first-line therapy for Pneumocystis jirovecii pneumonia and bacterial infections in critically ill patients, where acute kidney injury (AKI) and renal replacement therapy (RRT) are regularly observed. Both may change half-life and subsequent concentrations. Specifically, Trimethoprim (TMP) is eliminated renally, whereas sulfamethoxazole (SMX) elimination is 80%metabolic/20%renal. Despite decades of cotrimoxazole use, data in acute kidney injury (AKI) are scarce and no consensus on dosing strategy has been established. Besides, pharmacodynamic parameter has not been determined, leading to an uncertainty on the dosing regimen.

Full description

The objective is to compare the plasma concentrations of patients with acute renal failure (ARF) or requiring extra renal replacement therapy (RRT) with those of patients without these characteristics to look for differences in concentration.

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient hospitalized in Intensive Care Units between October 2020 and July 2021 with infection treated with cotrimoxazole

Exclusion criteria

• None

Trial design

5 participants in 1 patient group

patients in Intensive Care unit

Description:

patients in Intensive Care unit with infection treated with cotrimoxazole will be included. Data will be collected of medical record.

Treatment:

Other: Collect data of medical record